ArticleScientific reports2024
Systemic immune-inflammatory index predict short-term outcome in recurrent/metastatic and locally advanced cervical cancer patients treated with PD-1 inhibitor.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Platelet-to-lymphocyte ratio for prognostication in immune checkpoint inhibitor-treated cancer patients: a meta-analysis of 13027 patients highlighting nivolumab-responsive renal cell carcinoma.Frontiers in immunology · 2026Pooled it
- Prognostic significance of pretreatment systemic immune-inflammation index (SII) in patients with cervical cancer: a meta-analysis.World journal of surgical oncology · 2025Pooled it
- Article
- Early Tumor Shrinkage and Clinical Outcomes for Esophageal Squamous Cell Carcinoma Patients Treated with Immune Checkpoint Inhibitors: Real-World Observational Study.Annals of surgical oncology · 2026Observational
- Prognostic Value of the Systemic Immune-Inflammation Index in Advanced Endometrial Cancer Treated with Pembrolizumab-Lenvatinib: A Retrospective Real-World Study.Current oncology (Toronto, Ont.) · 2026Observational
- Nomogram for Preoperative Prediction of Adjuvant Therapy Requirement Following Radical Surgery in Stage IB Cervical Squamous Cell Carcinoma With Tumor Size ≤ 4 cm: A Retrospective Study.Cancer medicine · 2026Article
- Survival prediction in stage II/III rectal cancer: Role of immune-inflammatory biomarkers post neoadjuvant chemoradiotherapy.Oncology letters · 2026Article
- Systemic immune-inflammatory index for the prediction of the survival in patients with cervical cancer: A meta-analysis.iScience · 2026Article
- Article
- Real-world efficacy, safety, and associated biomarkers of cadonilimab in cervical cancer: a prospective observational study.Frontiers in immunology · 2026Observational
- Predictive value of the systemic immune-inflammation index combined with the prognostic nutritional index for postoperative recurrence in early-stage cervical cancer: evidence from a multicenter cohort study.Frontiers in oncology · 2026Article
- Combined neutrophil-to-lymphocyte ratio and nomogram for predicting progression-free survival in recurrent/metastatic cervical cancer treated with immune checkpoint inhibitors.Frontiers in immunology · 2026Article
- Systemic Inflammatory Indices-Systemic Immune-Inflammation Index (SII) and the Systemic Inflammation Response Index (SIRI)-As Potential Rule-Out Biomarkers for Invasive Cervical Carcinoma.International journal of molecular sciences · 2025Observational
- Peripheral lymphocyte count as a prognostic marker in cervical cancer patients treated with immune checkpoint inhibitors: a retrospective study.BMC cancer · 2025Article
- Nonlinear association between systemic immune-inflammation index and in-hospital mortality in critically ill patients with chronic obstructive pulmonary disease and atrial fibrillation: a cross-sectional study.Journal of thoracic disease · 2025Article
- The Platelet-to-Lymphocyte Ratio (PLR) as a Non-Invasive Biomarker for Cervical Malignancy in Conization Patients.Life (Basel, Switzerland) · 2025Article
- "Pre-Treatment" and "Post-Treatment" Systemic Inflammatory Markers: Is There Any Prognostic Role for Metastatic Cervical Cancer on Bevacizumab Containing Treatment?Medicina (Kaunas, Lithuania) · 2025Article
- The promise of PD1/PDL1 targeted immunotherapy in locally advanced cervical cancer: a game-changer for patients outcome?Frontiers in immunology · 2025Review
- Machine learning-based prediction of clinical outcomes in cervical cancer using routine hematological indices: development and web implementation.Frontiers in oncology · 2025Article
- Complete remission of recurrent human papillomavirus-associated cervical cancer managed with camrelizumab and nanoparticle albumin-bound paclitaxel as second-line treatment: a case report.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to assess the predictive value of certain markers of inflammation in patients with locally advanced or recurrent/metastatic cervical cancer who are undergoing treatment with anti-programmed death 1 (PD-1) therapy. A total of 105 patients with cervical cancer, who received treatment involving immunocheckpoint inhibitors (ICIs), were included in this retrospective study. We collected information on various peripheral blood indices, including the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index (SII), and prognostic nutritional index (PNI). To determine the appropriate cutoff values for these inflammatory markers, we performed receiver operating characteristic curve (ROC) analysis. Progression-free survival (PFS) was estimated using the Kaplan-Meier method, and we conducted both univariate and multivariate Cox regression analyses to evaluate the prognostic value of these markers. Out of the 105 patients who received ICI treatment, the median progression-free survival (mPFS) was 19.0 months. We obtained the patients' clinical characteristics, such as age, pathological type, therapy regimen, Figo stage, NLR, PLR, LMR, SII, and PNI from their medical records. The optimal cutoff values for NLR, PLR, LMR, SII, and PNI were determined as 3.76, 218.1, 3.34, 1147.7, 43.75, respectively. In the univariate analysis, age, pathological type, therapy regimen, Figo stage, and LMR were not found to be associated with PFS. However, high NLR(P=0.001), high PLR(P<0.001), high SII(P<0.001), and low PNI (P=0.003)were all associated with shorter PFS. Multivariate analysis indicated that SII (P=0.017) was an independent risk factor for PFS. This study highlights the potential use of SII as a predictor of progression-free survival in cervical cancer patients undergoing immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.